Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

BiomX Ltd.. (2/20/19). "Press Release: BiomX Raises $32 Million in Series B Financing. Proceeds Will Be Used Primarily to Advance Leading IBD and Acne Programs to the Clinic". Ness Ziona.

Organisations Organisation BiomX Ltd.
  Organisation 2 OrbiMed Israel Incubator LP
  Group OrbiMed (Group)
Products Product microbiomic treatment (live biotherapeutics)
  Product 2 venture capital
Index terms Index term BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al
  Index term 2 BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund
     


BiomX Ltd., a microbiome company developing customized phage therapies, today announced the closing of a $32 million series B equity financing. The financing was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I, SBI Japan-Israel Innovation Fund and additional European investors and included new investors led by RM Global Partners (RMGP) BioPharma Investment Fund, with participation from Chong Kun Dang Pharmaceutical Corp., Handok, Inc., KB Investment Co., Ltd. and Consensus Business Group. Proceeds from the financing will be used primarily to advance the Company’s leading drug candidates for the treatment of acne and Inflammatory Bowel Disease (IBD) to the clinic.

“We greatly appreciate the continued support of our existing investors as well as their guidance and assistance and are excited to welcome the new group of investors, led by RM Global Partners,” said Jonathan Solomon, CEO of BiomX. “The new funding will enable us to transition BiomX to a clinical stage company as our lead programs in acne and IBD, both novel phage therapeutics targeting harmful bacteria in the microbiome, enter the clinic. The acne program is expected to begin clinical trials by year-end, followed by our IBD program next year. In addition, we will continue to drive our liver disease and colorectal cancer programs forward by identifying key bacteria driving these diseases and developing unique phage cocktails against them.”

In conjunction with the investment, Yaron Breski, Managing Director at RM Global Partners, and Eric de la Fortelle, Ph.D., MBA, Venture Partner at Seventure Partners, join BiomX’s Board of Directors.

“Both phage therapeutics and the microbiome are receiving increased attention and enthusiasm, and BiomX is at the forefront of both fields,” said Rob Woodman, Ph.D., Senior Partner at Takeda Ventures, Inc. “We are very excited to continue our support and involvement as BiomX brings its breakthrough science and research into the clinic.”


About BiomX:

BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. www.biomx.com


Media contact

MacDougall
Shai Biran, Ph.D.
Direct: +1 781 235 3060
sbiran@macbiocom.com

   
Record changed: 2019-03-13

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for BiomX Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top